Chimera Biotec is a specialty CRO and immunoassay platform provider focused on ultra-sensitive and technically demanding bioanalysis for large-molecule therapeutics. Founded in 2000, the company has established itself as the world's leading Immuno-PCR technology vendor, offering services on its proprietary Imperacer® platform as well as other technologies like Simoa® and MSD. Its mission is to provide highly sensitive, accurate, and reliable bioanalytical data to support all phases of modern drug development, particularly for biologics, biosimilars, and biobetters, under strict GLP/GCP quality regimes.
Imperacer®, a proprietary Immuno-PCR platform that conjugates antibodies to DNA for exponential signal amplification via RT-qPCR, enabling ultra-sensitive detection of large-molecule analytes at sub-pg/ml concentrations.
Funding History
2
Total raised:$30M
Series B$20MCreathor Venture
Series A$10MHigh-Tech Gründerfonds
Opportunities
Growth is driven by the expanding biologics and biosimilars market, which demands highly sensitive bioanalysis.
Opportunities exist in expanding its biomarker and companion diagnostic services, leveraging AI research from its COVID-19 project, and potentially scaling its geographic reach while maintaining its niche expertise.
Risk Factors
Key risks include dependency on the outsourcing trends of biopharma, potential technological disruption from newer assay platforms, the challenge of retaining highly specialized scientific staff, and maintaining stringent regulatory compliance in its GLP-certified operations.
Competitive Landscape
Competes with large, broad-based CROs and other specialty bioanalytical service providers. Differentiates through its deep, 20+ year focus on ultra-sensitive immunoassays, proprietary Imperacer® technology, GLP certification, and a client service model led by PhD-level project managers.
